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SARS-CoV-2, the causative agent of COVID-19, uses the viral Spike (S) protein for host 28 
cell attachment and entry. The host protease furin cleaves the full-length precursor S 29 
glycoprotein into two associated polypeptides: S1 and S2. Cleavage of S generates a 30 
polybasic Arg-Arg-Ala-Arg C-terminal sequence on S1, which conforms to a C-end rule 31 
(CendR) motif that binds to cell surface Neuropilin-1 (NRP1) and Neuropilin-2 (NRP2) 32 
receptors. Here, using X-ray crystallography and biochemical approaches we show that 33 
the S1 CendR motif directly bound NRP1. Blocking this interaction using RNAi or 34 
selective inhibitors reduced SARS-CoV-2 entry and infectivity in cell culture. NRP1 thus 35 
serves as a host factor for SARS-CoV-2 infection and may potentially provide a 36 
therapeutic target for COVID-19. 37 
  38 
SARS-CoV-2 is the coronavirus responsible for the current COVID-19 pandemic (1,2). A 39 
striking difference between the S protein of SARS-CoV-2 and SARS-CoV is the presence, in 40 
the former, of a polybasic sequence motif, RRAR, at the S1/S2 boundary. It provides a cleavage 41 
site for a host proprotein convertase, furin (3-5) (Fig. S1A). The resulting two proteins, S1 and 42 
S2, remain non-covalently associated, with the serine protease TMPRSS2 further priming S2 43 
(6). Furin-mediated processing increases infectivity and affects the tropism of SARS-CoV-2, 44 
while furin inhibition diminishes SARS-CoV-2 entry, and deletion of the polybasic site in the 45 
S protein reduces syncytia formation in cell culture (3-5,7). 46 
 47 
The C-terminus of the S1 protein generated by furin cleavage has an amino acid sequence 48 
(682RRAR685), that conforms to a [R/K]XX[R/K] motif, termed the ‘C-end rule’ (CendR) (Fig. 49 
S1B) (8). CendR peptides bind to Neuropilin-1 (NRP1) and NRP2, transmembrane receptors 50 
that regulate pleiotropic biological processes, including axon guidance, angiogenesis and 51 




associate with neuropilins we generated a GFP-tagged S1 construct (GFP-S1) (Fig. S1C). 53 
When expressed in HEK293T cells engineered to express the SARS-CoV-2 receptor ACE2, 54 
GFP-S1 immunoprecipitated endogenous NRP1 and ACE2 (Fig. 1A). We transiently co-55 
expressed NRP1-mCherry and either GFP-S1 or GFP-S1 ΔRRAR (a deletion of the terminal 56 
682RRAR685 residues) in HEK293T cells. NRP1 immunoprecipitated the S1 protein, and 57 
deletion of the CendR motif reduced this association (Fig. 1B). Comparable binding was also 58 
observed with mCherry-NRP2, a receptor with high homology to NRP1 (Fig. S1D, S1E). In 59 
both cases, residual binding was observed with the ΔRRAR mutant indicating an additional 60 
CendR-independent association between neuropilins and the S1 protein.  61 
 62 
To probe the functional relevance of this interaction, we generated HeLa wild type and NRP1 63 
knock out (KO) cell lines stably expressing ACE2, designated as HeLawt+ACE2 and 64 
HeLaNRP1KO+ACE2 respectively (the level of ACE2 expression was comparable between these 65 
lines) (Fig. S1F). Using a clinical isolate SARS-CoV-2 (SARS-CoV-66 
2/human/Liverpool/REMRQ001/2020), we performed viral infection assays and fixed the cells 67 
at 6 and 16 hours post infection (hpi). SARS-CoV-2 infection was reduced in 68 
HeLaNRP1KO+ACE2 relative to HeLawt+ACE2 (Fig. 1C). HeLa cells lacking ACE2 expression 69 
were not infected (Fig. S1G). In Caco-2 cells, a human colon adenocarcinoma cell line 70 
endogenously expressing ACE2 and widely used in COVID-19 studies, the suppression of 71 
NRP1 expression by shRNA greatly reduced SARS-CoV-2 infection at both 7 and 16 hpi 72 
respectively, whereas that of vesicular stomatitis virus (VSV) pseudotyped with VSV-G was 73 
unaffected (Fig. 1D, S1H, S2A). To determine if NRP1 was required for early virus infection, 74 
we established a sequential staining procedure using antibodies against SARS-CoV-2 S and N 75 
proteins to distinguish extracellular and intracellular viral particles (Fig. S2B). While NRP1 76 




was halved in NRP1-depleted cells compared to control cells after 30 minutes of internalization 78 
(Fig. 1F). NRP1 therefore enhances SARS-CoV-2 entry and infection.  79 
 80 
We also observed that SARS-CoV-2-infected HeLawt+ACE2 cells displayed a multi-nucleated 81 
syncytia cell pattern, as reported by others (Fig. 1C) (5). Using an image analysis algorithm 82 
and supervised machine learning (Fig. S2C-F) (11), we quantified syncytia of infected 83 
HeLawt+ACE2 and HeLaNRP1KO+ACE2 cells. At 16 hpi, the majority of HeLawt+ACE2 cells 84 
formed syncytia, while in HeLaNRP1KO+ACE2 cells this phenotype was reduced (Fig. S2G). 85 
When infected with a SARS-CoV-2 isolate lacking the furin cleavage site (SARS-CoV-2 86 
ΔS1/S2) (Fig. S1A) the differences in infection and syncytia formation were less pronounced 87 
(Fig. S2H, S2I). However, a significant decrease in infection of HeLaNRP1KO+ACE2 was still 88 
observed at 16 hpi, indicating that NRP1 may additionally influence infection through a 89 
CendR-independent mechanism (Fig. S2H).  90 
 91 
The extracellular regions of NRP1 and NRP2 are composed of two CUB domains (a1 and a2), 92 
two coagulation factor domains (b1 and b2), and a MAM domain (9). Of these, the b1 domain 93 
contains the specific binding site for CendR peptides (Fig. S3A) (12). Accordingly, the 94 
mCherry-b1 domain of NRP1 immunoprecipitated GFP-S1, and a shortened GFP-S1 construct 95 
spanning residues 493-685 (Fig. S1C, S3B). Isothermal titration calorimetry (ITC) established 96 
that the b1 domain of NRP1 directly bound a synthetic S1 CendR peptide (679NSPRRAR685) 97 
with an affinity of 20.3 μM at pH 7.5, that was enhanced to 13.0 μM at pH 5.5 (Fig. 2A). 98 
Binding was not observed to a S1 CendR peptide in which the C-terminal arginine was mutated 99 
to alanine (679NSPRRAA685) (Fig. 2A). We co-crystallized the NRP1 b1 domain in complex 100 
with the S1 CendR peptide (Fig. 2B). The resolved 2.35 Å structure revealed 4 molecules of 101 




S3C). S1 CendR peptide binding displayed remarkable similarity to the previously solved 103 
structure of NRP1 b1 domain in complex with its endogenous ligand VEGF-A164 (Fig. 2B, S3D) 104 
(12). The key residues responsible for contacting the C-terminal R685 of the CendR peptide - 105 
Y297, W301, T316, D320, S346, T349 and Y353 - are almost identical between the two 106 
structures (Fig. 2B, S3D). The R682 and R685 sidechains together engage NRP1 via stacked 107 
cation-π interactions with NRP1 side chains of Y297 and Y353. By projecting these findings 108 
onto the structure of the NRP1 ectodomain, the b1 CendR binding pocket appears to be freely 109 
accessible to the S1 CendR peptide (Fig. S3E) (13). 110 
 111 
Site-directed mutagenesis of the S1 R685 residue to aspartic acid drastically reduced GFP-112 
S1493-685 immunoprecipitation by mCherry-b1, confirming the critical role of the C-terminal 113 
arginine (Fig. 2C). Mutagenesis of the T316 residue within the mCherry-b1 domain of NRP1 114 
to arginine also reduced association with GFP-S1493-685, consistent with its inhibitory impact on 115 
VEGF-A164 binding (12) (Fig. 2D). Accordingly, incubation of mCherry-b1 with VSV particles 116 
pseudotyped with trimeric S resulted in immunoprecipitation of processed forms of S1, which 117 
was dependent on the T316 residue (Fig. S3F). Next, we transiently expressed either GFP, full 118 
length NRP1 wt-GFP or full length NRP1-GFP harboring the T316R mutation in 119 
HeLaNRP1KO+ACE2 cells. GFP expression and ACE2 expression levels were comparable and 120 
both constructs retained similar cell surface localization (Fig. S3G, S3H). SARS-CoV-2 121 
infection was significantly enhanced in cells expressing NRP1 wt-GFP compared to GFP 122 
control, whereas it was not enhanced in cells expressing the T316R mutant (Fig. 2E). Thus, 123 
the SARS-CoV-2 S1 CendR and NRP1 interaction promotes infection. 124 
 125 
To establish the functional relevance of the S1 CendR-NRP1 interaction, we screened 126 




All three bound to the NRP1 b1b2 domain, displayed staining by immunofluorescence in 128 
NRP1-expressing PPC-1 (human primary prostate cancer) cells but not in M21 (human 129 
melanoma) cells that do not express NRP1 (Fig. S4A) (8), and stained the extracellular domain 130 
of NRP1-GFP expressed in cells (Fig. S4B). Of these antibodies, mAb#3, and to a lesser extent 131 
mAb#1, bound to the CendR-binding pocket with high specificity, as defined by reduced ability 132 
to bind to a b1b2 mutant that targets residues (S346, E348, T349) at the opening of the binding 133 
pocket (Fig. 3A) (12). Incubation of Caco-2 cells with mAbs#1 and 3, reduced SARS-CoV-2 134 
infection compared to a control mAb targeting avian influenza A virus (H11N3) hemagglutinin 135 
(Fig. 3B). Consistent with this, mAb#3 inhibited binding of GFP-S1493-685 and mCherry-b1 (Fig. 136 
3C). As a comparison, Caco-2 and Calu-3 cells were incubated with soluble ACE2, which 137 
inhibited SARS-CoV-2 infection in both cases (Fig. S4C). 138 
 139 
Next, we turned to the small molecule EG00229, a selective NRP1 antagonist that binds the b1 140 
CendR binding pocket and inhibits VEGF-A binding (Fig. 3D) (14). ITC established that 141 
EG00229 bound to the NRP1 b1 domain with a Kd of 5.1 and 11.0 μM at pH 7.5 and 5.5 142 
respectively (Fig. 3E). EG00229 inhibited the direct binding between b1 and the S1 CendR 143 
peptide, and the immunoprecipitation of GFP-S1493-685 by mCherry-b1 (Fig. 3E and S4D). 144 
Finally, incubation of Caco-2 cells with EG00229 reduced the efficiency of SARS-CoV-2 145 
infection at 7 and 16 hpi (Fig. 3F). Thus, the SARS-CoV-2 interaction with NRP1 can be 146 
targeted to reduce viral infectivity in relevant human cell lines (Fig. S5). 147 
 148 
Cell entry of SARS-CoV-2 depends on priming by host cell proteases (5,6,15). Our data 149 
indicate that a component of SARS-CoV-2 S protein binding to cell surface neuropilins occurs 150 
via the S1 CendR motif generated by the furin cleavage of S1/S2. While not affecting cell 151 




physiologically relevant cell lines widely used in the study of COVID-19. The molecular basis 153 
for the effect is unclear, but neuropilins are known to mediate the internalization of CendR 154 
ligands through an endocytic process resembling macropinocytosis, (8,16,17). Interestingly, 155 
gene expression analysis has revealed an up-regulation of NRP1 and NRP2 in lung tissue from 156 
COVID-19 patients (18). A SARS-CoV-2 virus with a natural deletion of the S1/S2 furin 157 
cleavage site demonstrated attenuated pathogenicity in hamster models (19). NRP1 binding to 158 
the CendR peptide in S1 is thus likely to play a role in the increased infectivity of SARS-CoV-159 
2 compared with SARS-CoV. The ability to target this specific interaction may provide a route 160 
for COVID-19 therapies. 161 
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Fig. 1. NRP1 Interacts with S1 and enhances SARS-CoV-2 infection. (A) HEK293T cells 294 
transduced to express ACE2 were transfected to express GFP or GFP-tagged S1 and lysed after 295 
24h. The lysates were subjected to GFP-nanotrap and the immune-isolates were blotted for 296 
ACE2 and NRP1 (N=3). (B) HEK293T cells were co-transfected to express GFP-tagged S1 or 297 
GFP-S1 ΔRRAR and mCherry or mCherry-tagged NRP1 and subjected to GFP-nanotrap (N=5). 298 
Two-tailed unpaired t-test; P= 0.0002. (C) HeLawt+ACE2 and HeLaNRP1 KO+ACE2 cells were 299 
infected with SARS-CoV-2. Cells were fixed at 6 or 16 hpi and stained for N protein (magenta) 300 
and Hoechst (cyan), and virus infectivity was quantified (N=3). Two-tailed unpaired t-test; 301 
P=0.00002 and 0.00088. Scale bar=200 µm. (D) Caco-2 cells expressing shRNA against NRP1 302 
or a non-targeting control (SCR) were infected with SARS-CoV-2 and fixed at 7 or 16 hpi. The 303 
cells were stained for N protein (magenta) and Hoechst (cyan), and infectivity was quantified 304 
(N=3). Two-tailed unpaired t-test; P=0.0005 and 0.00032. Scale bar=500 µm. (E) Caco-2 305 
shSCR or shNRP1 cells were inoculated with MOI=50 of SARS-CoV-2 and incubated in the 306 
cold for 60 min, and fixed. A two-step antibody staining procedure was performed using anti-307 
S and -N Abs to distinguish external (green) and total (red) virus particles, and the binding of 308 
particles per cell was quantified for over 3300 particles per condition (N=3). Two-tailed 309 
unpaired t-test; P=0.6859. (F) Caco-2 shSCR or shNRP1 cells were bound with SARS-CoV-2 310 
as in (E), followed by incubation at 37 oC for 30 min. The cells were fixed and stained as in 311 
(E). Viral uptake was quantified for over 4200 particles per condition (N=3). Two-tailed 312 
unpaired t-test; P=0.00079. Scale bars for (E) and (F) = 10 µm and 200 nm (zoom panels). The 313 
square regions were zoomed in. 314 
The bars, error bars, circles and triangles represent the mean, SEM (B) and SD (C-F), 315 
individual data points, respectively. ∗P< 0.05, ∗∗P< 0.01, ∗∗∗P< 0.001, ∗∗∗∗P< 0.0001. 316 








Fig. 2. Molecular basis for CendR binding of SARS-CoV-2 S1 with NRP1. (A) Binding of 319 
NRP1 b1 with native (green line) and mutant (orange line) form of S1 CendR peptide 320 
(corresponding to residues 679-685) by ITC at two different pH conditions (N=3). All ITC 321 
graphs represents the integrated and normalized data fit with 1-to-1 ratio binding. (B) Left: 322 
NRP1 b1 – S1 CendR peptide complex superposed with NRP1 b1 – VEGF-A fusion complex 323 
(PDB ID: 4DEQ). Bound peptides are shown in stick representation. RMSD = root mean square 324 
deviation. Right: Enlarged view highlighting the binding of S1 CendR peptide b1. Key binding 325 
residues on b1 are shown in stick representation. (C). HEK293T cells were co-transfected with 326 
combinations of GFP-tagged S1493-685 and S1493-685 R685D, and mCherry or mCherry-NRP1 327 
b1, and subjected to mCherry-nanotrap (N=5). Two-tailed unpaired t-test; P <0.0001. (D). 328 
HEK293T cells were co-transfected with combinations of GFP-tagged S1493-685 and mCherry, 329 
mCherry-NRP1 b1 or mCherry-NRP1 b1 T316R mutant and subjected to mCherry-nanotrap 330 
(N=5). Two-tailed unpaired t-test; P <0.0001. (E) HeLaNRP1KO + ACE2 cells transfected with 331 
GFP, NRP1 wt-GFP or NRP1 T316R-GFP constructs were infected 24 h later with SARS-332 
CoV-2. At 16 hpi the cells were fixed and stained for SARS-CoV-2-N, and viral infection 333 
quantified in the GFP-positive subpopulation of cells (N=3). The percentage of infection was 334 
normalized to that of GFP-transfected cells. Two-tailed unpaired t-test; p = 0.002. The bars, 335 
error bars and circles represent the mean, SEM (C-D) and SD (E), individual data points, 336 
respectively. ∗P< 0.05, ∗∗P< 0.01, ∗∗∗P< 0.001, ∗∗∗∗P< 0.0001. 337 
 338 
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Fig. 3. Selective inhibition of the S1-NRP1 interaction reduces SARS-CoV-2 infection. (A) 343 
ELISA of anti-NRP1 monoclonal antibodies (mAb#1, mAb#2, mAb#3) at 3 µg/mL using 344 
plates coated with NRP1 b1b2 wild type, b1b2 mutant (S346A, E348A, T349A) or BSA, used 345 
as control (N=3). Binding is represented as arbitrary units of absorbance at 655 nm. Two-tailed 346 
unpaired t-test; P = 0.0207, 0.2430, 0.0007. (B) Cells were pre-treated with 100 µg/mL of anti-347 
H11N3 (Ctrl) mAb, mAb#1, 2 or 3 for 1 h prior to infection with SARS-CoV-2. Cells were 348 
fixed at 16 hpi and stained for N protein (magenta) and Hoechst (cyan) (N=3). Two-tailed 349 
unpaired t-test; P=0.015, 0.36, 0.0003. Scale bar=500 µm. (C) HEK293T cells were co-350 
transfected with combinations of mCherry or mCherry-b1 and GFP-tagged S1493-685 and 351 
subjected to mCherry-nanotrap with or without co-incubation with mAb#3 (N=3). Two-tailed 352 
unpaired t-test; P = 0.0143.  (D) NRP1 b1 – S1 CendR peptide complex superimposed with 353 
NRP1 b1 – EG00229 inhibitor complex (PDB ID:3I97). Key binding residues on b1, bound 354 
peptides and EG00229 are shown in stick representation. (E) ITC analysis of EG00229 binding 355 
to b1 domain of NRP1 at two different pH conditions. Pre-incubation with EG00229 blocks S1 356 
CendR peptide binding (orange line), and the CendR peptide can reduce binding of EG00229 357 
(green line). (N=3). All ITC graphs represents the integrated and normalized data fit with 1-to-358 
1 ratio binding. (F). Cells were pre-treated with 100 µM of EG00229 or DMSO prior to 359 
infection with SARS-CoV-2. Cells were fixed at 7 and 16 hpi and stained for N protein 360 
(magenta) and Hoechst (cyan) (N=3). The square region was zoomed in. Scale bars=500 µm 361 
and 100 µm (zoom panel). Two-tailed unpaired t-test; P = 0.0059 and 0.0013. The bars, error 362 
bars, circles and triangles represent the mean, SEM (C) and SD (A, B, F) and individual data 363 
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Materials and Methods 30 
Antibodies and reagents 31 
The following antibodies were used in this study: mouse anti-β actin (Sigma-Aldrich, A1978, WB 32 
1:2000), mouse anti-ACE2 (Proteintech, 66699-1-Ig, WB 1:1000), mouse anti-GFP (Roche, 33 
11814460001, WB 1:2000), rabbit anti-mCherry (Abcam, ab167453, WB 1:2000), rabbit anti-34 
NRP1 (Abcam, ab81321, WB 1:1000), rabbit anti-SARS-CoV-2 Spike RBD (S1 epitope) (Sino 35 
Biologicals, 40592-T62, WB 1:1000), rabbit anti-SARS nucleocapsid (N) polyclonal antibody 36 
(ROCKLAND, 200-401-A50, IFA 1:2000), mouse anti-SARS-CoV-2 Spike antibody [1A9] (S2 37 
epitope) (GeneTex, GTX632604, WB 1:1000). Recombinant human ACE2 was purchased from 38 
Sino Biological (10108-H08H). EG 00229 trifluoroacetate was purchased from Tocris (6986). The 39 
monoclonal antibody against the hemagglutinin of influenza A/duck/New 40 
Zealand/164/76(H11N3) was a kind gift of Robert Webster. 41 
 42 
Cell culture and transfection 43 
Calu-3, Caco-2 (a kind gift from Dr Darryl Hill), Caco-2 shSCR and shNRP1 (a kind gift from 44 
Giuseppe Balistreri), HeLa, HEK293T and Vero E6 cell lines were originally sourced from the 45 
American Type Culture Collection. Authentication was from the American Type Culture 46 
Collection. We did not independently authenticate the cell lines. Cells were grown in DMEM 47 
medium (Sigma-Aldrich) supplemented with 10% (vol/vol) FCS (Sigma-Aldrich) and 48 
penicillin/streptomycin (Gibco) with the exception of Calu-3 cells that were grown in Eagle’s 49 
minimal essential medium (MEM+GlutaMAX; GibcoTM, ThermoFischer) supplemented with 10% 50 
FCS 0.1mM non-essential amino acids (NEAA), 1mM sodium pyruvate, 100 IU/ml streptomycin 51 




0.1mM NEAA. FuGENE HD (Promega) was used for transient transfection of DNA constructs 53 
for infection assays according to the manufacturer’s instructions.PPC-1 human primary prostate 54 
cancer cells were obtained from Erkki Ruoslahti laboratory at Cancer Research Center, Sanford-55 
Burnham-Prebys Medical Discovery Institute. M21 human melanoma cells were obtained from 56 
David Cheresh at University of California San Diego. Cos-7 cells were obtained from Urs Greber 57 
laboratory. Cells were cultured in DMEM medium containing 100 IU/mL of streptomycin, 58 
penicillin, and 10% FBS in 37°C incubator with 5% CO2. 59 
 60 
To generate a NRP1-null HeLa cell line, the following guide RNA (gRNA) was cloned into 61 
pSpCas9(BB)-2A-Puro (PX459): 5’-GATCGACGTTAGCTCCAACG-3’. gRNA was transfected 62 
into HeLa cells using FuGENE HD. 24 hours later, transfected cells were selected with puromycin. 63 
Selected cells were trypsinised and diluted to a concentration of 2.5 cells mL-1 in Iscove’s modified 64 
Dulbecco’s medium (Gibco) supplemented with 10% (vol/vol) FBS (Sigma-Aldrich). 200 µL of 65 
this suspension was plated into 96-well plates to seed single cell colonies. After three weeks, 66 
colonies were expanded and lysed, and knockout was validated by immunoblotting for NRP1. 67 
 68 
Generation of stable lentiviral cell lines 69 
The genes of interest were subcloned into the lentiviral vector pLVX for the generation of lentiviral 70 
particles. Lentiviral particles were produced and harvested in HEK293T cells. HeLa cells were 71 
transduced with lentiviral particles to produce stably expressing cell lines. Following transduction, 72 






SARS-CoV-2 isolation and infection 76 
A clinical specimen in viral transport medium, confirmed SARS-CoV-2 positive by qRT-PCR 77 
(kindly proved by Dr Lance Turtle, University of Liverpool), was adjusted to 2 ml with OptiMEM 78 
(Gibco™, ThermoFisher), filtered through a 0.2 µm filter and used to infect Vero E6 cells. After 79 
1 h the inoculum was diluted 1:3 (vol/vol) with MEM supplemented with 2% FCS and incubated 80 
at 37 °C in a 5% CO2 incubator for 5 days. The culture supernatant was passaged twice more on 81 
Vero E6 cells until cytopathic effect was observed and then once on Caco-2 cells to produce the 82 
stock used in the experiments. The intracellular viral genome sequence and the titre of virus in the 83 
supernatant were determined as previously described (20) and the virus termed SARS-CoV-84 
2/human/Liverpool/REMRQ0001/2020. A stock of the SARS-CoV-2 strain SARS-CoV-2 strain 85 
England/2/2020 (VE6-T) containing a mixture of the wild type virus and a virus in which 86 
the RRAR furin cleavage site had been deleted (SARS-CoV-2 ΔS1/S2) (20) was serially diluted 87 
(10-fold dilutions) in MEM supplemented with 2% FCS and added to either Vero E6 or Caco-2 88 
cells in a 96 well plate. After 5 days incubation at 37 °C in 5% CO2, the culture supernatants in 89 
wells showing CPE at the highest dilution were again diluted and passaged on the same cells. After 90 
a further 5 days incubation, a 20 µl aliquot of culture supernatant from wells showing CPE at the 91 
highest dilution were used for RNA extraction and RT-PCR using a primer set designed to 92 
discriminate the wild type and SARS-CoV-2 ΔS1/S2 viruses. Culture supernatants containing 93 
either the wild type virus or the SARS-CoV-2 ΔS1/S2 virus, with no sign of a mixed virus 94 
population were used to produce large scale stocks in Vero E6 cells. The presence of the expected 95 
virus in the stocks was verified by direct RNA sequencing using an Oxford Nanopore flow cell as 96 
previously described (18). For virus infections, virus was added directly to culture medium of the 97 




16 h. The culture supernatant was removed, and the cells fixed with 4% (vol/vol) 99 
paraformaldehyde (PFA) for 1 h at room temperature.  All work with infectious SARS-CoV-2 was 100 
done inside a class III microbiological safety cabinet in a containment level 3 facility at the 101 
University of Bristol. 102 
 103 
Pseudotyped virus generation 104 
The VSVΔG system was a kind gift from Stefan Pöhlmann, and used to generate pseudovirus 105 
particles decorated with SARS-2-S or VSV-G as described previously (5, 21) with some 106 
modifications. Briefly, HEK293T cells were grown in 100 mm diameter dishes to 90% confluency 107 
and were subsequently transfected with 6 μg of pCG1_SARS-2-S or pCMV-VSV-G plasmid using 108 
polyethylenimine (PEI) Max (MW = 40,000KDa, Polysciences, Germany) as transfection reagent. 109 
Transfection was performed using a PEI:DNA ratio of 4:1 in serum free DMEM for 4 hours at 110 
37oC. The cells were then washed with PBS and cultured in fresh complete DMEM supplemented 111 
with 5% FBS at 37oC overnight. The next day cells were exposed to the replication deficient 112 
VSV*ΔG-fLuc vector (kindly provided by Markus Hoffmann, German Primate Center, Leibnitz) 113 
for 2 hours at 37oC. The cells were then washed with PBS before the addition of medium 114 
supplemented with anti-VSV-G I1 antibody (kindly provided by Markus Hoffmann, German 115 
Primate Center, Leibnitz). No I1 antibody was added to VSV-G expressing cells. The cells were 116 
further incubated at 37oC for 24 hours before the supernatant was harvested and clarified by 117 
centrifugation at 2,000 x g for 10 minutes. For immunoprecipitation experiments, VSV pseudoviral 118 
particles were concentrated 10-fold using 100KDa Amicon® Ultra centrifugal filter units. 119 
 120 




For infection assays, cells seeded in Clear 96-well Microplates (Greiner Bio-one) were infected 122 
with SARS-CoV-2/human/Liverpool/REMRQ001/2020 isolate in MEM, 2% FCS, supplemented 123 
with 0.1mM NEAA and fixed in 4% PFA in PBS at 16 h.p.i. After permeabilisation with 0.1% 124 
TritonX-100 in PBS, 1% BSA, the cells were blocked and stained in 1% BSA in PBS containing 125 
anti-SARS Nucleocapsid (N) rabbit polyclonal antibody or anti-SARS Spike (S) monoclonal 126 
antibody and further stained with Hoechst (1:10000) and appropriate Alexa Fluor (488/594/647)-127 
conjugated secondary antibodies (Thermo Fisher Scientific). The stained plates were imaged using 128 
an automated high-content spinning-disk microscope CQ1 (Confocal Quantitative Image 129 
Cytometer, Yokogawa, Japan) using UPlanSApo 10x/0.4na, UPlanSApo 20x/0.75na or 130 
UPlanSApo 40x/0.95na objectives (Olympus, Japan). To capture a single 96-well, 20 fields (with 131 
10x objective) or 80 fields (20x) were imaged by z-stacks at 5 μm intervals and maximum intensity 132 
projected for analysis. Yokogawa CQ1 imaging was performed with four excitation laser lines 133 
(405/488/561/640nms) with spinning disc confocal.  134 
 135 
Virus binding and uptake assay 136 
SARS-CoV-2 wt was inoculated at an MOI=50 on Caco-2 cells grown in Clear 96-well 137 
Microplates (Greiner Bio-one) and allowed to bind to the cell surface in the cold on a chilled metal 138 
plate for 60 min. For the binding assay, cells were fixed immediately after. For the virus uptake 139 
assay, the inoculum was removed after binding and incubated for 30 min on a pre-warmed metal 140 
block at 37 ℃ in the presence of 1 mm cycloheximide, and fixed. To distinguish extracellular and 141 
intracellular viral particles, a two-step, dual staining procedure was used using antibodies against 142 
SARS-CoV-2 S and N, in that order. Briefly, the fixed cells were blocked in PBS, 1% BSA for 30 143 




with goat anti-rabbit Alexa Fluor 488 (1:2500) and wheat germ agglutinin conjugated with Alexa 145 
Fluor 647 (1:250) for 30 min, washed and fixed for 15 min in 4% FA in PBS. The cells were then 146 
permeabilized for 2 min in PBS, 1% BSA, 0.1% Tx-100, washed and stained with anti-N (1:2000) 147 
for 60 min at room temperature, then washed and stained with goat anti-rabbit Alexa Fluor 594 for 148 
30 min to stain all extracellular and intracellular viral particles. Hoechst was used to stain nuclei. 149 
Where indicated phalloidin conjugated to Alexa Fluor 647 (1:250) was used to image actin 150 
filaments. The cells were imaged using the Yokogawa CQ1 automated spinning-disk microscope 151 
with a UPlanSApo 40x/0.95na objective (Olympus, Japan), acquiring 20 z-stacks at 0.6 µm 152 
intervals using 4 channels. Nine to 16 fields of view were captured via well and the resulting MIP 153 
images were used for image analysis using the Cell Path Finder software (Yokogawa). 154 
 155 
Cell immunostaining and confocal microscopy 156 
PPC-1, M21 and HeLa cells were seeded in a 24-well plate (50,000 cells/well) with coverslips and 157 
allowed to grow until the next day. The medium was removed, the cells were washed twice with 158 
PBS pH 7.4, and fixed with 4% PFA in PBS for 10 min at room temperature. The cells were 159 
washed twice with PBS and once with PBST (PBS with 0.05 % Tween-20). Blocking buffer (5% 160 
BSA, 5% FBS, 5% goat serum in PBST) was added to the cells and incubated for 1 h at room 161 
temperature. The blocking buffer was removed, and 0.3 mL of monoclonal antibodies were added 162 
to the cells (mAB diluted 1 in 5 in diluted blocking buffer containing 1% BSA, 1% FBS, 1% goat 163 
serum in PBST). Cells were incubated for 1 h at room temperature and washed 3 times with PBST. 164 
Secondary antibody AlexaFluor 546 goat anti-mouse IgG (Invitrogen Molecular Probes, Cat. No. 165 
A11003) was added to the cells (4µg/mL in diluted blocking buffer). Cells were incubated for 30 166 




at room temperature. After three washes with PBS, the cells were mounted on glass slides with 168 
mounting media (Fluoromount-G; Electron Microscopy Sciences) and sealed with nail polish. A 169 
confocal microscope FV1200MPE (Olympus, Japan) was used for cell imaging of PPC-1 and M21 170 
cells with an UPlanSApo 60x/1.35na objective (Olympus, Japan). The images were analyzed using 171 
Olympus FluoView Ver.4.2a Viewer software. HeLa cells were imaged with a confocal laser 172 
scanning microscope (SP5II AOBS, Leica Microsystems) attached to an inverted epifluorescence 173 
microscope (DMI600, Thermo Fischer Scitentific) with a 40X/1.25na objective. Fluorescence 174 
intensity of surface NRP1 was quantified using Volocity software. 175 
 176 
Image analysis 177 
Projected images taken with a 20x objective were used for image analysis for single-cell and 178 
multinucleated cell infection image analysis with supervised machine learning. Image processing 179 
was performed using the BIAS software (Single-Cell Technologies Inc., Hungary). Firstly, images 180 
of each fluorescence channel were corrected using the CIDRE illumination correction method (22). 181 
Individual cell nuclei were detected by a deep machine learning-based segmentation algorithm 182 
NucleAIzer (11). Cellular cytoplasm were detected both on the green and red channels using 183 
UNET to enhance fluorescence images (23). The method was trained to precisely delineate often 184 
faint signals in the cytoplasm. Cellular phenotypes were assigned to each individual nucleus. These 185 
are infected cells which contain a single nucleus (Single Cell Infection), those that contain more 186 
multiple nuclei (Multi Nuclei Infection) as observed in the distinct cell-cell fusion syncytia 187 
phenotype. Supervised machine learning was used for phenotypic assignment. The decisions were 188 




statistics include the number of multi-nucleated cells, the average number of nuclei in these cells 190 
and the count of other phenotypic classes. Yokogawa CQ1 was also used for image quantification. 191 
 192 
Immunoprecipitation and quantitative western blot analysis  193 
Cells were lysed in PBS with 1% Triton X-100 and protease inhibitor cocktail for western blotting. 194 
The protein concentration was determined using a BCA assay kit (Thermo Fisher Scientific) and 195 
equal amounts were resolved on NuPAGE 4–12% precast gels (Invitrogen). Blotting was 196 
performed onto polyvinylidene fluoride membranes (Immobilon-FL, EMD Millipore), followed 197 
by detection using the Odyssey infrared scanning system (LI-COR Biosciences). When using the 198 
Odyssey, we routinely performed western blot analysis where a single blot was simultaneously 199 
probed with antibodies against two proteins of interest (distinct antibody species), followed by 200 
visualization with the corresponding secondary antibodies conjugated to distinct spectral dyes. The 201 
band intensities, normalized to actin expression, are presented as the average fraction of protein 202 
abundance relative to control conditions. 203 
 204 
For the GFP- and mCherry-based immunoprecipitations, HEK293T cells were transfected with 205 
GFP or mCherry constructs using PEI (Sigma-Aldrich). The cells were lysed in 206 
immunoprecipitation buffer (50mM Tris–HCl, 0.5% NP-40 PBS with protease inhibitor cocktail 207 
(Roche)) 24hr after transfection and subjected to GFP-trap (ChromoTek) or RFP-tap (ChromoTek) 208 
beads. To inhibit immunoprecipitation of GFP-S1 constructs, EG00229 or mAb#3 were added to 209 
the immunoprecipitation buffer at the indicated concentrations, DMSO and PBS were respectively 210 
used as controls. Following immunoprecipitation, the beads were washed twice in 50mM Tris-211 




with protease inhibitor cocktail, pH 7.5, before boiling in 2X LDS sample loading buffer for 213 
elution. Immunoblotting was performed using standard procedures. Detection was performed on 214 
an Odyssey infrared scanning system (LI-COR Biosciences) using fluorescently labelled 215 
secondary antibodies. Band intensities are normalized to the amount of immunoprecipitated 216 
protein levels (of GFP-tagged constructs for GFP-nanotrap experiments, and of mCherry-tagged 217 
constructs for mCherry-nanotrap experiments). The band intensities are then presented as the 218 
average fraction of immunoprecipitated protein abundance relative to the amount 219 
immunoprecipitated in control conditions. 220 
 221 
For immunoprecipitation of the VSV-Spike pseudotyped virus, mCherry, mCherry-b1 and 222 
mCherry-b1 T316R were transfected into HEK293T cells the day before immunoprecipitation. 223 
Cells were lysed in 50mM Tris-HCl 0.5% NP40 PBS with protease inhibitor cocktail, pH 7.5. 224 
Lysates were cleared by centrifugation at 20,000 g for 10 minutes at 4°C. From the resulting 225 
supernatant, an input fraction was reserved, and the rest incubated with RFP-trap beads to rotate 226 
for 1 hour at 4°C. Following enrichment of mCherry constructs, the beads were washed twice in 227 
50mM Tris-HCl 0.25% NP40 PBS with protease inhibitor cocktail, pH 7.5, and twice in 50mM 228 
Tris-HCl PBS with protease inhibitor cocktail, pH 7.5, to remove residual cell lysate and detergent. 229 
VSV-Spike pseudotyped virus was added to the isolated mCherry beads and incubated rotating for 230 
a further 1 hour at 4°C. Following virus immunoprecipitation, the beads were again washed twice 231 
in 50mM Tris-HCl 0.25% NP40 PBS with protease inhibitor cocktail, pH 7.5, and twice in 50mM 232 
Tris-HCl PBS with protease inhibitor cocktail, pH 7.5, before boiling in 2X LDS sample loading 233 





Recombinant NRP1 b1 and b1b2 soluble protein expression and purification 236 
The sequence encoding the human NRP1 b1 domain composed of residues 273-427 was 237 
synthesized and sub-cloned into the pET28a(+) at NdeI and XhoI restriction sites, for bacterial 238 
expression with an N-terminal His-tag. The protein was expressed in Rosetta-gamiTM 2 (DE3) cells 239 
(Novagen) similar to the protocol described previously (25, 26). In brief, the protein was expressed 240 
in Terrific-Broth at 37°C until OD600 reached 1.5. The culture was then cooled 15 min at 4°C prior 241 
to induction with 1 mM isopropyl β-D-thiogalactopyranoside (IPTG). The culture was further 242 
expressed for ~16 h at 16°C before harvesting. Cell pellets were lysed using a constant system TS-243 
series cell disruptor in lysis buffer containing 50 mM Tris-HCl (pH 7.5), 300 mM NaCl, 50 μg/ml 244 
benzamidine and DNase I. The homogenate was cleared by centrifugation and loaded onto Talon® 245 
resin (Clonetech) using standard affinity purification procedures. Removal of the His-tag was 246 
performed by adding thrombin (Sigma-Aldrich) into the eluted fraction together with dialysis 247 
overnight in the lysis buffer at 4°C. The cleaved and uncleaved fractions were then separated using 248 
reverse metal affinity chromatography. The His-tag cleaved fraction was collected and further 249 
purified by gel filtration using Superdex 75 16/60 column in either neutral pH buffer containing 250 
50 mM Tris-HCl pH 7.5, 150 mM NaCl or acidic buffer containing 50 mM sodium citrate pH 5.5, 251 
150 mM NaCl.   252 
 253 
Wild-type and triple mutant human NRP1 b1b2 domain (residues 274-584) were expressed 254 
in Escherichia coli strain Rosetta-gami-2 (Novagen, Madison, WI) as a His-tag fusion in pET28b 255 
(Novagen). Cells were grown in Terrific-Broth at 37°C to an OD600 = 1.2 and, after 15 min at 256 
4°C, induced with 1 mM IPTG. After growth at 16°C for 16 h, cells were harvested by 257 




St. Louis, MO) nickel affinity resin in 20 mM Tris (pH 8.0) and 400 mM NaCl with an imidazole 259 
gradient from 25-500 mM. Further purification was performed on 5 ml hitrap heparin column 260 
(GE). Protein was loaded in 20mM Tris pH=8.0, 100mM NaCl and eluted using a linear gradient 261 
100-800 M NaCl. Final purification was performed using Superdex 75 16/100 (Amersham 262 
Pharmacia) column equilibrated in 20mM Tris pH 8.0, 150mM NaCl. 263 
  264 
Generation of monoclonal antibodies against NRP1 b1b2 265 
Female BALB/c and C57BL/6 mice, 8–9 weeks old, were immunized intraperitoneally with 17 μg 266 
of recombinant NRP1 b1b2 mixed with an equal volume of complete Freund's adjuvant (Sigma–267 
Aldrich Chemie, Steinheim, Germany), followed by a booster immunization four weeks later of 268 
the same dose mixed with incomplete Freund's adjuvant (Sigma–Aldrich). Mice received three 269 
boosts of the same amount of antigen in PBS on days −3, −2, and −1 prior to fusion. Spleens were 270 
excised and the splenocytes were fused with myeloma cells (P3X63Ag8.653) according to a 271 
previously described protocol (25). Beginning on day 10 after fusion, hybridoma supernatants 272 
were screened for specific antibodies. Before experiments, the hybridoma supernatants were 273 
centrifuged at 300g for 5 min at room temperature and 500 µl dialyzed against 2 L of PBS over 274 
night at 4°C prior use. 275 
 276 
 277 
ELISA assay with monoclonal antibodies 278 
High affinity protein-binding 96-well plates (NuncTM MaxisorpTM Cat No. 442404) were coated 279 
with 1 µg of protein (100 µL of 10 µg/mL of protein solution in PBS) overnight at 37°C. The wells 280 




0.1%Tween-20 in PBS). The mAb dilutions in blocking buffer were added to the wells and 282 
incubated for 1 h at 37°C. The wells were washed 5 times with blocking buffer and the peroxidase-283 
conjugated affinity pure donkey anti-mouse IgG (Immuno Research Laboratories) was added 284 
(diluted 1 in 20.000 in blocking buffer). The plate was incubated for 1 h at 37°C and washed 5 285 
times with blocking buffer. The peroxidase substrate (TMB Peroxidase EIA Substrate Kit 286 
#1721067, Bio-Rad) was added as described in the manufacturer instructions. The absorbance of 287 
the samples was read at 655 nm using Tecan Sunrise microplate reader (Tecan, Switzerland). 288 
 289 
Statistical analysis 290 
Statistical analyses were performed using Prism 7 (GraphPad Software). Graphs represent means 291 
and SEM or SD, N represent biological replicates. The statistical test used for each experiment is 292 
always stated in the corresponding figure legends. For all statistical tests, P < 0.05 was considered 293 




pLVX-IRES-BSD was generated by replacing the puromycin resistance cassette in pLVX-IRES-298 
puro (Clontech) with a blasticidin resistance gene (BSD) using HiFi DNA assembly (New England 299 
Biolabs) according to the manufacturer’s instructions. The primers used were 5’-300 
TAGACGCGTCTGGAACAATC-3’ and 5’-GGAAGGTCGTCTCCTTGTG-3’ for the pLVX 301 
vector fragment, and 5’-ccacaaggagacgaccttccATGGCCAAGCCTTTGTCTC-3’ and 5’-302 





ACE2 was amplified by PCR using cDNA generated from human A549 cells as template. The 305 
primers used were 5’-agaactcgagaccATGTCAAGCTCTTCCTGGCTC-3’ and 5’-306 
tgtttctagaCTAAAAGGAGGTCTGAACATCATCAG-3’ and carried an XhoI or an XbaI 307 
restriction site, respectively. The amplicon was digested with XhoI and XbaI and ligated into the 308 
digested pLVX-IRES-BSD vector. All plasmids were verified by Sanger sequencing. 309 
 310 
The SARS-CoV-2 S gene was cloned into pLVX vectors using a commercially synthesized EGFP-311 
S gene fusion plasmid (the S gene sequence was that of SARS-CoV-2 isolate Wuhan-Hu-1; 312 
GenBank: MN908947.3; GeneArt, ThermoFischer) as a template by Gibson assembly (NEB). For 313 
the untagged version, in brief, the S gene was amplified using overlapping primers and cloned into 314 
a ‘pLVX-MCS-T2A-Puro’ vector previously digested with EcoRI/BamHI. The isolated S1 315 
constructs and S1 truncations were amplified from commercially synthesized plasmids (GeneArt, 316 
ThermoFischer) encompassing nucleotides 20021 – 22960 and 22891 – 28830 of the SARS-CoV-317 
2 isolate Wuhan-Hu-1 genome (GenBank: MN908947.3) and cloned in pEGFP.C1 using 318 
KpnI/BamHI. Mouse Nrp1-mCherry was a kind gift from Donatella Valdembri. pEGFP-NRP1 319 
and pEGFP-NRP2 were kind gifts from Mu-Sheng Zeng. mCherry-tagged NRP1 and NRP2 320 
constructs were subcloned from pEGFP-NRP1 and pEGFP-NRP2. 321 
 322 
Isothermal Titration Calorimetry  323 
ITC experiments were conducted at 30°C using a Microcal ITC200 (Malvern) in buffer containing 324 
either 50 mM Tris-HCl pH 7.5, 150 mM NaCl (for neutral pH condition) or 50 mM sodium citrate 325 
pH 5.5, 150 mM NaCl (for acidic pH condition). To test the binding between NRP1 b1 and S1 326 




mutant forms of the peptide in the range of 700 μM to 900 μM were titrated into 40 μM of NRP1 328 
b1 domain. The same protein/peptide concentrations and buffer conditions were applied to 329 
examine the interaction between NRP1 b1 and EG00229 inhibitor. The competitive effects of 330 
EG00229 on NRP1 b1 binding to the S1 CendR peptide was tested by pre-mixing 40 μM of NRP1 331 
b1 with either 160 µM of EG00229 or S1 CendR peptide, and then titrating with 700 μM of either 332 
S1 CendR peptide or EG00229 in the ITC syringe respectively. In all cases, the experiments were 333 
carried out with an initial 0.4 μl injection (not used in data processing) followed by 12 serial 334 
injections of 3.22 μl each with 180 s intervals. The thermodynamic parameters Kd, ∆H, ∆G and -335 
T∆S were analyzed with Malvern software package by fitting and normalized data to a single-site 336 
binding model (Tables S1, S2). The stoichiometry was refined initially, and if the value was close 337 
to 1, then N was set to exactly 1.0 for calculation. All experiments were performed at least 2 to 3 338 
times to check for reproducibility of the data.  339 
 340 
Crystallization and Data Collection  341 
All crystallization experiments were performed using hanging drop vapor diffusion under 96-well 342 
format at 20°C. For co-crystallization, 7X molar excess of native S1 CendR peptide (the same 343 
peptide used for ITC) was added to the purified NRP1 b1 in 50 mM sodium citrate pH 5.5, 150 344 
mM NaCl at a final protein concentration of 11 mg/ml. Crystals were observed in many different 345 
commercial screen conditions after 5 days, with most of the conditions containing acidic buffer 346 
with pH ranges from 5 to 6.5. The best quality crystals were obtained in a condition composed of 347 
0.1 M sodium citrate pH 5, 20% PEG 6000. Prior to the data collection, crystals were soaked in 348 




and 8X molar excess of S1 CendR peptide. Diffraction data were collected to 2.36 Å on the MX1 350 
beamline at the Australian Synchrotron at 100 K.  351 
 352 
Structure Determination 353 
Diffraction data were indexed and integrated by AutoXDS and scaled using Aimless (26, 27). A 354 
molecular replacement solution using NRP1 b1 domain (PDB ID: 1KEX) as template was obtained 355 
by the program Phaser (30). Electron density for the S1 CendR peptide was readily observable 356 
after the molecular replacement. More specifically, electron density corresponding to the last two 357 
residues at the C-terminal tail of the CendR peptides, A684 and R685, could be interpreted in all 358 
four copies of the complex in the asymmetric unit without any refinement. In one particular copy, 359 
the electron density corresponding to the entire 7 residues of the S1 CendR peptide was visible for 360 
model building and figure display. Structure refinement was carried out using the PHENIX 361 
software suite with iterative rebuilding of the model (31). The program Coot was used for model 362 
rebuilding guided by Fo - Fc difference maps. After iterative rounds of refinement, the quality and 363 
geometry of the refined structure was evaluated using MolProbity (32). Data collection and 364 
refinement statistics are summarized in Table S3. Structural alignment was performed by using 365 
the DALI server and molecular graphics were generated using PyMOL (33).  366 
 367 
Data Deposition 368 
Coordinates and structure factors for the NRP1 b1 - S1 CendR peptide complex have been 369 
deposited at the Protein Data Bank (PDB) with accession code 7JJC. All the relevant raw data 370 
related to this study is available from the corresponding authors on request.  371 












Fig.  S1. The SARS-CoV-2 S1 protein contains a CendR motif. (A) Alignment of the S protein 378 
sequence of SARS-CoV and SARS-CoV-2. SARS-CoV-2 S possesses a furin cleavage site at the 379 
S1/S2 boundary that is absent in the SARS-CoV-2 ΔS1/S2 mutant. (B) Table highlighting the 380 
similarity between the C-terminal sequence of SARS-CoV-2 S1 and the CendR motifs of 381 
established NRP1 ligands. (C) Summary of constructs used in this study. TM = 382 
transmembrane. (D) SARS-CoV-2 S1 interacts with NRP2. HEK293T cells were co-transfected 383 
to express mCherry, mCherry-tagged Nrp1 or mCherry-tagged NRP2, and GFP-tagged S1, then 384 
subjected to mCherry-nanotrap (N=3). Two-tailed unpaired t-test; P= 0.2421. (E) CendR motif 385 
dependent interaction of the SARS-CoV-2 S1 with NRP2. HEK293T cells were co-transfected to 386 
express GFP-tagged S1 or GFP-S1 ΔRRAR and mCherry or mCherry-tagged NRP2, then 387 
subjected to mCherry-nanotrap. (N=4). Two-tailed unpaired t-test; P = 0.0175. (F) Quantification 388 
of ACE2 levels in HeLawt+ACE2 and HeLaNRP1KO+ACE2 cells (N=3). Two-tailed unpaired t-test; 389 
P=0.1065. (G) HeLawt and HeLawt+ACE2 were infected with SARS-CoV-2, fixed 16 hpi and 390 
infection was quantified (N=3). Scale bar = 200 µm. (H) Caco-2 cells were transfected with a 391 
control shRNA (shSCR) an anti-NRP1 shRNA (shNRP1). Following western blotting of cell 392 
lysates, NRP1 and ACE2 bands were quantified (N=3). Two-way ANOVA and Sidak’s test; 393 
NRP1: P < 0.0001, ACE2: P = 0.374. 394 
The bars, error bars and circles represent the mean, SEM and individual data points, 395 
respectively. ∗P< 0.05, ∗∗P< 0.01, ∗∗∗P< 0.001, ∗∗∗∗P< 0.0001.  396 
 397 




Fig. S2.  399 
 400 




Fig. S2. Image processing and phenotyping of SARS-CoV-2 infected cells. (A) Caco-402 
2 shSCR and shNRP1 cells were infected with VSV pseudotyped with VSV-G for 16 hours, fixed, 403 
and detected by GFP reporter expression (N=3). Two-tailed unpaired t-test. P=0.3187. Scale bar = 404 
500 µm. (B) Schematic of the two-step staining procedure used to distinguish external from 405 
internal virus particles. (C) Original image of SARS-CoV-2 N signal (green) and enhanced image 406 
(red) using UNET deep learning algorithm. (D) Single-cell segmentation of the nuclei 407 
using the nucleAIzer deep learning algorithm, and the cytoplasmic region based on 408 
global thresholding of the UNET enhanced image. (E) Morphology, shape and intensity features 409 
of single-cells and their microenvironment are extracted. Features include morphology, intensity 410 
and texture descriptor numbers. Ci: features of the i-th cell, Cj: features of the j-th cell.  (F) 411 
Machine learning-based phenotyping of single cells into non-infected, single-nuclei infected and 412 
multinucleated cells. (G) Ratio of syncytia and single cell infection phenotypes in HeLawt+ACE2 413 
and HeLaNRP1 KO+ACE2 cells infected with SARS-CoV-2. Cells were fixed at 16 hpi and stained 414 
for N protein (magenta) and Hoechst (cyan), and cell phenotypes were quantified (N=3). Scale bar 415 
= 20 µm. (H) HeLawt+ACE2 and HeLaNRP1 KO+ACE2 cells were infected with SARS-CoV-2 416 
ΔS1/S2. Cells were fixed at 6 or 16 hpi and stained as in (G), and virus infectivity was quantified 417 
(N=3). Two-tailed unpaired t-test; P=0.12 and P<0.0001. Scale bar=200 µm. (I) Ratio of syncytia 418 
and single cell infection phenotypes in HeLawt+ACE2 and HeLaNRP1 KO+ACE2 cells infected with 419 
SARS-CoV-2 ΔS1/S2. Cells were fixed and stained as in (G). Scale bar = 20 µm.  420 
The bars, error bars, circles and triangles represent the mean, SD and individual data points, 421 
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Fig.  S3. Extended molecular insights into the S1-NRP1 interaction (A) Schematic of 427 
CendR motif binding to the NRP1 b1 domain. (B) HEK293T cells were co-transfected with 428 
combinations of mCherry-b1, and GFP, GFP-tagged S1 or S1493-685 and subjected to GFP-nanotrap 429 
(N=3). Two-tailed unpaired t-test; P = 0.0050. (C) Ribbon representation of NRP1 b1 – 430 
S1 CendR peptide complex. The electron density shown corresponds to a simulated-annealing 431 
OMIT Fo – Fc map of S1 CendR peptide contoured at 3σ. For clarity, the S1 CendR peptide binds 432 
to chain C of NRP1 B1 domain showing the electron density from N679 to R685 was selected for 433 
structural analysis and figure display. (D) Left: NRP1 b1 – S1 CendR peptide complex superposed 434 
with NRP1 b1 – VEGF-A fusion complex (PDB ID: 4DEQ). Right: enlarged view highlighting 435 
the binding of VEGF-A227-232 to NRP1 b1. Bound peptides and key binding residues on b1 are shown 436 
in stick representation. (E) NRP1 b1 – S1 CendR peptide complex superposed with NRP1 437 
a1a2b1b2 structure (PDB ID: 4GZ9). (F) HEK293T cells were co-transfected with mCherry, 438 
mCherry-NRP1 b1 or mCherry-NRP1 b1 T316R and the mCherry-tagged proteins were captured 439 
on mCherry-beads. VSV-S pseudoparticles were then added and subjected mCherry-440 
nanotrap (N=3). (G) HeLaNRP1 KO+ACE2 cells were transfected with GFP, NRP1 wt-GFP or NRP1 441 
T316R-GFP and lysed 24 h later (N=3). GFP levels: Two-tailed unpaired t-test, P = 0.1167. ACE2 442 
levels: one-way ANOVA and Dunnett’s test; +NRP1 wt-GFP vs + GFP, P = 0.5293; +NRP1 wt-443 
GFP vs + NRP1 T316R-GFP, P = 0.9672. (H) IF staining of HeLaNRP1KO + ACE2 transfected with 444 
NRP1 wt-GFP and NRP1 T316R-GFP. Non-permeabilised cells were labelled with anti-NRP1 445 
mAb#3, and signal intensity was quantified using Volocity software (N=3, 88 cells per 446 
condition). Two-tailed unpaired t-test; P = 0.9829. Scale bar = 50 µm and 20 µm (zoom panel). 447 
The bars, error bars and circles represent the mean, SEM and individual data points, 448 
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Fig. S4. Validation of selective inhibitors for SARS-CoV-2 infection. (A) Fluorescence 452 
confocal images of non-permeabilised NRP1-positive PPC-1 and NRP1-negative M21 cells 453 
incubated with mAb#1, #2 and #3 (N=2). Antibody staining (red) and DAPI (blue) are 454 
shown. Scale bar=20 µm. (B) Fluorescent spinning-disk confocal images of Cos7 cells expressing 455 
human NRP1-GFP using mAb#1, #2, #3 and ctrl mAb against influenza HA. Non-permeabilised, 456 
fixed cells in 96-well plates were incubated with the mAbs (1:10 dilution) for 1 h and 457 
immunostained with the secondary antibody AlexaFluor 594 goat anti-mouse IgG. Z- stack images 458 
were acquired using a 20x objective and maximum projections are shown (N=3). Blue: Hoechst; 459 
Green: GFP; Red: antibody signal. Scale bar=10 μm. (C) Inhibition of SARS-CoV-2 infection by 460 
treatment with recombinant soluble ACE2 in Caco-2 and Calu-3 cells. Cells were pre-treated 461 
with soluble ACE2 (10 μg/mL) for 1 h prior to SARS-CoV-2 infection. At 16 hpi the cells were 462 
fixed and stained for N protein and infection was quantified (N=3). Two-tailed unpaired t-test; 463 
P=0.0005 and 0.0008. (D) EG00229 inhibits GFP-S1493-685 immunoprecipitation. HEK293T cells 464 
were co-transfected with GFP-tagged S1493-685 and mCherry or mCherry-b1, and subjected to 465 
a mCherry-nanotrap in the presence of the indicated concentrations of EG00229 or DMSO 466 
(N=6). Ordinary one-way ANOVA with Dunnett’s multiple comparisons test, P = 0.9996 (0.15 467 
µM), 0.9866 (0.8 µM), 0.4265 (4 µM), 0.0473 (20 µM) and 0.0041 (100 µM). The bars, error bars, 468 
circles and triangles represent the mean, SD (C) and SEM (D) respectively. 469 
∗P< 0.05, ∗∗P< 0.01, ∗∗∗P< 0.001, ∗∗∗∗P< 0.0001.  470 
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Fig. S5. Model of neuropilin binding in SARS-CoV-2 infection. The S1 protein of SARS-CoV-474 
2 associates to neuropilins through CendR peptide recognition by the neuropilin b1 domain. This 475 
interaction promotes SARS-CoV-2 entry and infection in physiologically relevant cell lines. The 476 
ability to target this specific interaction may provide a route for COVID-19 therapies.  477 















S1 CendR peptide (pH 7.5)a 
Native  20.3 ± 2.0 -3.4 ± 0.8 -6.5 ± 0.06 -3.1 ± 0.8 1 
R685A  No binding detected 
S1 CendR peptide (pH 5.5)b 
Native  13.0 ± 1.3  -7.4 ± 0.6 -6.8 ± 0.06 0.6 ± 0.7 1 
R685A No binding detected 
a. Experiment performed in buffer containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl.  481 
b. Experiment performed in buffer containing 50 mM Sodium citrate pH 5.5, 150 mM 482 
NaCl. 483 
c. Stoichiometry was refined and fixed as 1.0 for calculation.  484 




Table S2. Thermodynamic parameters for the binding of NRP1 B1 domain with EG00229 486 










Titrating EG00229 into NRP1 B1 
pH 7.5a 5.1 ± 0.3  -10.7 ± 0.5 -7.4 ± 0.04 3.3 ± 0.5 1.0 
pH 5.5b 9.7 ± 0.2 -11.8 ± 0.6 -7.0 ± 0.01 4.8 ± 0.6  1.0 
Titrating EG00229 into NRP1 B1 + S1 CendR peptide 
pH 7.5a 6.3 ± 0.7 -4.5 ± 0.3 -7.2 ± 0.07 -2.7 ± 0.2  1.0 
pH 5.5b 14.7 ± 1.5 -2.2 ± 0.1 -6.7 ± 0.06 -4.5 ± 0.2 1.0 
Titrating S1 CendR peptide into NRP1 B1 + EG00229 
In pH 7.5 condition >300  -4.1 ± 1.6 -4.8 ± 0.07 -0.7 ± 1.8 1.0 
In pH 5.5 condition >300 -5.7 ± 0.5 -4.8 ± 0.04 0.9 ± 0.5 1.0 
a. Experiment performed in buffer containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl.  488 
b. Experiment performed in buffer containing 50 mM Sodium citrate pH 5.5, 150 mM 489 
NaCl. 490 
c. Stoichiometry was refined and fixed as 1.0 for calculation.  491 




Table S3. Summary of crystallographic structure determination statistics 493 
Data collection statistics 7JJC 
Space group P212121 
Resolution (Å) 46.39 – 2.36 
(2.45 – 2.36) 
a, b, c (Å) 
α,  β, γ (°) 
89.93, 89.89, 108.30 
90, 90, 90 
Total observations 276,344 (27,837) 
Unique reflections 36,732 (3,656) 
Completeness (%) 99.6 (96.2) 
Rmerge+ 0.100 (1.478) 
Rpim* 0.039 (0.565) 
CC1/2 0.999 (0.613) 
<I/σ(I)> 11.4 (1.0) 
Multiplicity 7.5 (7.6) 
Molecule/asym. 4 
Refinement statistics  
Rwork/Rfree (%) ¶# 20.2/24.9 
No. protein atoms, Ligand (peptide), Waters 5217, 128, 144 
Wilson B (Å2) 50.6 
Average B (Å2)^ 54 
       Protein (chain A/B/C/D) 52/53/51/55 
       S1 CendR peptide (chain E/F/G/H) 79/81/87/90 
       Water 51 
rmsd bonds (Å), angles (°) 0.003, 0.687 




Values in parentheses refer to the highest resolution shell. +Rmerge = Σ|I – <I> | ⁄ Σ<I>, where I is the intensity of each individual reflection. *Rpim 494 
indicates all I+ & I-. ¶Rwork = Σh|Fo - Fc|/ Σl| Fo|, where Fo and Fc are the observed and calculated structure-factor amplitudes for each reflection h. 495 
#Rfree was calculated with 10% of the diffraction data selected randomly and excluded from refinement. ^Calculated using Baverage. 496 
 497 
 498 
